Trial reportHaematologica2014
A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.
Trial report in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Inflammatory and Immune Microenvironment in Myeloproliferative Neoplasms: Pathogenic Mechanisms and Therapeutic Opportunities.Cancers · 2026Review
- High-selective HDAC6 inhibitor alleviates bone marrow fibrosis through inhibiting collagen formation and extracellular matrix deposition.Scientific reports · 2025Article
- HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.Blood · 2020Article
- Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.Frontiers in immunology · 2020Review
- Erythropoiesis: insights into pathophysiology and treatments in 2017.Molecular medicine (Cambridge, Mass.) · 2018Review
- Novel Therapies for Myelofibrosis.Current hematologic malignancy reports · 2017Review
- Pharmacotherapy of Myelofibrosis.Drugs · 2017Review
- How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Current hematologic malignancy reports · 2016Review
- Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.OncoTargets and therapy · 2016Review
- Setting Appropriate Goals for the Next Generation of Clinical Trials in Myelofibrosis.Current hematologic malignancy reports · 2015Review
- Current and future treatment options for polycythemia vera.Annals of hematology · 2015Review
- Review
- Novel therapies for myelofibrosis.Leukemia & lymphoma · 2015Review
- Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.Mediators of inflammation · 2015Review
- Novel myelofibrosis treatment strategies: potential partners for combination therapies.Leukemia · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.